Pipeline Review on Post Menopausal Osteoporosis – H1 2020 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Post Menopausal Osteoporosis – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis – Pipeline Review, H1 2020, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape.

Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. Treatment includes hormone replacement therapy (HRT) and vitamin D analogues.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Post Menopausal Osteoporosis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide also reviews key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 1, 8, 1, 8, 3 and 9 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. (Read more…) The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

• Ablynx NV
• AlphaMab Co Ltd
• Amgen Inc
• Aryogen Pharmed Co
• Entera Bio Ltd
• Enteris BioPharma Inc
• Enzene Biosciences Ltd
• Epygen Biotech Pvt Ltd
• Genor BioPharma Co Ltd
• Hengenix Biotech Inc
• Hualan Biological Engineering Inc
• InSight Biopharmaceuticals Ltd
• Intas Pharmaceuticals Ltd
• Ipsen SA
• JHL Biotech Inc
• Jiangsu T-mab BioPharma Co Ltd
• Lupin Ltd
• Luye Pharma Group Ltd
• Metabolab Inc
• Nano Intelligent Biomedical Engineering Corp
• Nanomedic Inc
• NeuClone Pty Ltd
• Paras Biopharmaceuticals Finland Oy
• Qilu Pharmaceutical Co Ltd
• Reliance Life Sciences Pvt Ltd
• Sandoz International GmbH
• Shandong Danhong Pharmaceutical Co Ltd
• Shanghai Biomabs Pharmaceuticals Co Ltd
• Shenzhen Salubris Pharmaceuticals Co Ltd
• Uni-Bio Science Group Ltd
• USV Pvt Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/6edh95

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900